Project Grant R01AR084711
- This $366,639 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) supports research to understand the mechanisms driving poor outcomes in women with dermatomyositis, a rare autoimmune disease. The key objectives are to: 1) Establish the Southern California Dermatomyositis Disease Network, a patient-centered registry to recruit diverse patients with dermatomyositis and...
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
- This federal Project Grant award of $528,558.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The goal of the research project is to study the immune system mechanisms underlying treatment resistance and paradoxical inflammatory side effects in patients with atopic dermatitis who receive the antibody therapy dupilumab. The research will...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,070,827 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Icahn School of Medicine at Mount Sinai. This grant aims to identify novel microbial factors that can enhance wound repair, a significant public health issue with over 100 million new acute skin wounds annually and substantial treatment costs exceeding $25 billion. The...
- This $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify differences in DNA regulatory elements that control gene expression in skin cells from individuals of different ancestral backgrounds. The research team at the Icahn School of Medicine at Mount Sinai will utilize advanced genomic techniques, including...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $216,113 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Weill Medical College of Cornell University. The grant funding will support research to target the GDF15-GFRAL signaling pathway to prevent and treat cachexia (muscle wasting) in a mouse model of mitochondrial myopathy. Specifically, the research aims to determine if inhibiting the GDF15-GFRAL...
- This federal Project Grant award of $172,584.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting a 5-year research career development program. The award recipient, The Trustees of Columbia University in the City of New York, will utilize multi-omics analyses to prioritize potentially causal genes associated with systemic sclerosis (SSc), a serious autoimmune...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $439,791 Project Grant to The University of Texas Southwestern Medical Center on March 1, 2025 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports research to investigate the molecular mechanisms of myoblast fusion, which is essential for skeletal muscle development and regeneration. The research aims to understand the cellular and...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), awarded a $726,898 Project Grant to Weill Medical College of Cornell University. The grant, awarded on August 1, 2025, will support a research project titled "Personalized Immunomonitoring to Understand Juvenile Dermatomyositis" with Principal Investigators Pascual, V. and Wilson, P. The project aims to improve understanding of the pathogenesis of juvenile dermatomyositis (JDM), a rare autoimmune disorder affecting children, through comprehensive analysis of patient immune profiles. The research will utilize single-cell transcriptional profiling and other advanced techniques to characterize immune cell populations and develop new diagnostic and prognostic biomarkers for JDM. The project is scheduled for completion by June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $726.9k | 7/31/25 |